secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001193125-25-242652
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo prices $135M offering; FDA open to faster LX2006 approval path
--------------------------------------------------------------------

- Priced public offering of 15.625M shares at $8.00 and $10M private placement (pre-funded warrants) to Balyasny; gross proceeds ~$135M.
- Preliminary cash, cash equivalents and investments of $122.8M as of Sept 30, 2025.
- FDA indicated openness to accelerated BLA for LX2006 using pooled Phase I/II and pivotal study data; enhanced manufacturing comparability required.
- LX2006 interim data: sustained or deepening improvements in LVMI and frataxin in majority of 16 participants at >=6 months follow-up.
- LX2020: 9 participants dosed; one Grade 3 SVT resolved; low-dose cohort shows stable cardiac parameters; more data expected Jan 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000119312525242652/0001193125-25-242652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000119312525242652/d52644d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-242652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer